Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

NCT03397706 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Epstein-Barr Virus-Associated Lymphoma
Lymphoproliferative Disorders

Interventions

COMBINATION_PRODUCT: VRx-3996 and valganciclovir

Sponsor

Viracta Therapeutics, Inc.